SOX9 and cancer: Treatment with the NTN1 antibody decreased FAK phosphorylation, downregulated ZEB1 and SOX9, reduced Ki-67+ proliferating cancer cells, and also decreased PGP9.5+ and TH+ nerves (Fig. 6I and J; Supplementary Fig. S7B–E).